Hi, good afternoon. Welcome to the Jefferies Global Healthcare Conference in London. My name is Dennis Ding, biotech and specialty pharma analyst here at Jefferies. I have the wonderful pleasure of having Verrica Pharmaceuticals here. We have the CEO, Jayson Rieger. Welcome.
Thank you.
Before we get started, why don't you just give a little bit of overview around Verrica in 2026 and some of the progress, some of the things that you guys have done this year.
Thank you very much. It's exciting to be here today and talk about Verrica and what we've accomplished over the last year. Team has worked very hard to expand both the access, distribution, and utilization of YCANTH, our drug device combination product approved for molluscum contagiosum in the U.S. It is also approved in Japan with our partner, Shionogi Pharmaceuticals. If you're not aware, molluscum is a pox virus, very similar to chickenpox, but unlike chickenpox, it can persist for 12 to 18 months, and on average about 13 months if left untreated. Historically, the major competitor to the product was do nothing and watch and wait mentality because there was nothing. We're now very excited to have YCANTH available. It can be treated by pediatricians, dermatologists, and other primary care clinicians, as well as any medical professional in the doctor's office.
We've seen significant growth over the last year in both volume and revenue, so we're very excited about that. We're also really excited about the ongoing phase III programs we have in common warts, which will leverage the same drug device combination product for utilization in the common wart indication, which is about a prevalence of 22 million patients in the U.S. alone, versus about 6 million prevalence estimated for molluscum. I'll share some more information on that. I'm sure you'll have questions on the common wart trials.
Perfect. When you think about the commercial strategy at Verrica, that's kind of changed from last year to this year. Maybe describe some of those changes and how you're thinking about the commercial organizations, also the strategy moving forward.
Sure. Because YCANTH is a clinician-administered product, patients have to go to the doctor's office to get the drug. That actually presents an opportunity both for revenue generation by the clinician for actually doing a procedure to help clear the disease, but also make sure the disease is actually treated. Oftentimes with take-home products or topicals, especially in dermatology, compliance is not nearly what it is in the clinical studies, and so real-world efficacy tends to be diminished relative to what is seen in the clinical studies.
As we have rolled out YCANTH, what we've seen in the commercial use, we're now well over 100,000 applicators dispensed commercially, has been efficacy comparable to perhaps better than we saw in our clinical studies, and a safety profile that's equally as good or perhaps better than what we saw in our clinical studies, representing that diverse use by multiple clinicians, it represents efficacy and satisfaction for the patients. The commercial sales force, rather than being dedicated to pediatric or dermatology or primary care, they focus on a ZIP code. In those areas, patients may get diagnosed by the pediatrician who wants to treat, and so that we train that pediatrician to treat. Oftentimes, there can be pediatricians who want to refer to their colleague as a dermatologist, and they'll refer to that dermatologist.
That Verrica representative works very hard to manage that ecosystem in that local community, which makes it more efficient for our representatives, more efficient for our sales force and our distribution. Now we have set up access for a non-dispensing pharmacy through the brand YCANTH Rx. If clinicians can write to that hub, the hub can help identify the coverage for the patient and how best to get it fulfilled, where to route that to a specialty pharmacy and get it shipped right to the doctor's office. In many cases now, commercially insured patients can pay as little as $0 for that initial fill as well as potentially for refills.
Okay. Can you just give us a little bit of background in terms of how the drug is administered and how you're measuring compliance and things like that?
Sure. When a patient comes in and they're diagnosed with molluscum, the clinician will write the prescription for YCANTH. It will be delivered within a few days to a week or two, depending on the patient usually answering the phone for the pharmacy to run the insurance. When they come in, the drug is applied in-office. It can take as little as five to 10 minutes. The drug is a drug device combination film-forming agent inside that applicator. Each of the lesions is coated with the smallest amount of drug, forms a thin film over the lesion, results. The drug's mechanism is vesicant, forms a small little blister, that destroys the lesion and stimulates your immune system to help clear the virus effectively.
Just this last quarter, we published additional data from our phase III studies that showed the treatment with YCANTH accelerated clearance by about 4x and increased the probability of clearance about 3x relative to placebo. That really goes to speak that watch and wait versus actual treatment makes a big difference, and these patients don't have to suffer with these lesions and the potential scarring, infection, et cetera, that can result from no treatment.
Sure. Earlier on, you mentioned there's around 6 million patients, I think, in the U.S.-
Yes.
-with molluscum. You're also talking about going after peds and also dermatologists. It usually requires a fairly large commercial sales force.
Yes.
What is your strategy in terms of targeting that sales force? How do you decide which ones to target? Then should we expect the sales force to grow as you go into 2027 just to capture more of the TAM?
We're constantly evaluating the size of our sales force and how they're deployed. We've identified a number of surrogates, because there is no predicate product or anything in this category for treatment, we can look at destruction codes of, are these lesions being destroyed? We can look at other high-prescribing clinicians in the area to understand those who see a lot of patients and have patient volume. We have a few other products we can use as surrogates for identifying those clinicians. Our representatives target, as you would expect, high-decile potential prescribers, but we also leverage a lot of non-promotional field force as well as regional conferences and national conferences to get that engagement with the clinician.
One of the things we focus on tremendously is good engagement, good training, and a good experience for those clinicians, because they're the ones who are going to see those patients in the future, and treat it. This is an acute disease, so the clinician is the primary customer that we need to make sure understands how to use it and has good experience.
We believe that our sales force works efficiently in that way, and the inner community referral network is very powerful for increasing those referrals.
Got it. Okay. When you look at YCANTH's revenue trajectory, you guys have grown, but still revenue, it's still a little bit more modest relative to the 6 million patients that are out there.
Absolutely.
What are ways that you are thinking about just accelerating revenue growth?
We thought about a lot of things on this front. The first thing we wanted to do was make sure there was receptivity and interest in the product, and we've done that over the last few quarters, where we made sure the clinician got access to the drug in a reliable, consistent way. The company invested heavily in our copay support program to make sure that when a doctor writes a prescription, the patient gets it, whether they're on either Medicaid or commercially provided insurance plans. Since then, we've now worked hard to optimize the yield and the experience and efficiency of those scripts getting there.
We've invested very carefully in expanding our sales force in a moderate way to understand the best practices for the identification of the clinician, the delivery of the drug, and that experience, and then we'll continue to explore if there is a need for expanding that sales force. But recently, we just achieved our goal of 50 sales reps in the field in the major areas where you'd want to have them. As we think about that field force, the foundation it's building, as we think about the other indications, common warts in particular for YCANTH, this drug can be used there. It would be predominantly the same clinicians who are prescribing.
We can get tremendous leverage from the experience of the underlying clinicians if common warts is approved.
Okay. I think a part of this is also awareness, right? Physician awareness of the product, but also patient awareness of this. How are you approaching that? Where do you think awareness is right now, and what are ways to do to improve that?
I think awareness, we are still in the early stages of creating that opportunity, which is why we believe there could be significant growth in the underlying opportunity to treat molluscum, as well as the underlying potential for common warts. We are leveraging trade shows, conferences, social media, and speaker programs to really help build that engagement. We are not planning on a large consumer-based advertising program. Those are incredibly expensive, especially for a modest cost, acute disease. That is why we are targeting those to build that foundation with the clinicians, education through school programs, medical schools, and training programs, because that is how you build the foundation of the business.
Typically, how many sales rep visits does it take for a doctor to start prescribing?
It really does depend. For dermatologists who are familiar with disease, have used compounded products or other products historically for treating molluscum, the advantages of this become very apparent to them. As soon as they know how to access it, that conversion rate is usually smaller. For pediatricians who have typically referred away, it can take a few more visits, but we find that they also tend to be very sticky because they like the product, they get familiar with the product, and they can get comfortable with the product. And we encourage them to adopt it slowly, utilize it, and get very comfortable, because they have historically not treated, and it is a procedure.
But it is something that is very advantageous to them. And I hear all the time, they see this disease all the time, and they would like a treatment, and this is something that they really can do in their office. And it can be the nurse, the physician assistant, or the clinician.
Anyone in the office can treat once they're trained.
Have you talked about the depth of prescribing that you guys have right now? Meaning, have you disclosed how many docs have prescribed it more than once or three times and five times, et cetera? What are ways to really drive that depth?
We've not disclosed that yet. One of the initiatives that we certainly will work on more this year is taking those early adopters and getting them to be more frequent prescribers, and those who are prescribing frequently could continue to expand that growth. What you'll find in some pediatric offices, which often have 10 or 12 or more providers in that office, there will be a handful that are procedure-oriented and wanting to do it and become the experts on YCANTH and molluscum, and there are others who want to refer away. So in that office, they will refer and create. So what we find is some of that data is less transparent in terms of who's doing the prescribing and who's doing the treating, but we're getting a much better sense of that data now.
I think our plan is to next year start to describe and share some of that data with you.
Got it. Something else that I want to talk about is access.
Okay.
Right? And pricing. And you guys put in place some initiatives last year around sampling or free drugs to get doctors familiar with it.
How have those efforts been and when should we expect net price to kind of start improving?
Those efforts last year, like I said, on copay support and sampling were to get familiarity with the drug. The best way to get a doctor comfortable with it is to give them a placebo one to train with and give them samples to treat the first patients and see how those experiences work. What we also have now set up is YcanthRx, our non-dispensing pharmacy hub, where they can help facilitate insurance coverage for those patients.
Because this is covered both under the medical benefit and the pharmacy benefit, if a doctor writes it to a local pharmacy and that pharmacy doesn't have a contract with that payer, it won't get covered.
The non-dispensing pharmacy allows for that to get funneled more efficiently. This last quarter, you can see on relatively flat volume, we saw a meaningful increase in yield.
I think that's due to those efforts we started to put in place last year, as we're seeing that conversion of scripts that would have gone either unpaid or underpaid to getting fully paid.
Mm-hmm. Have you talked about where gross-to-net would be eventually at steady state levels?
We have not disclosed that, but we are working to continue to improve yield. We think there is still yield to be achieved, and we will continue to share that information as it becomes available. Obviously, most pharma companies have a floor which you can get to, but I think that we've still got some room to grow based on the investment we made in our copay program last year and what we're trying to claw back some of that yield this year.
Okay. How should investors think about YCANTH growth in 2027?
We believe we're still in the early stages of YCANTH penetration in the market. One of the things that we're focusing on is both the short term and the long term for this product, particularly as we think about data next year for our common wart indication, and that same call point with the same product for that.
The most important thing we can do is drive high volume and repeatable, reliable writers. That's going to set the foundation for the future, and we think that will support the growth both through this year and into next year.
Right. Maybe we can segue over to the common warts program. You guys are in phase III. I think you have two studies that are ongoing, and we'll get data fairly shortly, right? In the first quarter of 2027.
Correct. The first trial is fully enrolled, we'll read out in Q1 of next year. The second trial we've announced was more than halfway done, and we expect to have data by mid-next year. We also did conduct an interim promising zone power analysis for the first trial, and that concluded that no additional patients were recommended.
Okay.
It gives us more confidence in the outcome of that study based on the study design and the phase II results we showed earlier.
Mm-hmm. How should we think about the opportunity in common warts? I think earlier you said molluscum was 6 million, common warts was 22 million, so it's meaningfully larger, but what are ways that you can do to actually capture that opportunity?
I think first off, it's going to be many of the same clinicians, which helps in the familiarity with the product and the access.
It is a much larger addressable market. Common warts are typically larger lesions and thicker lesions, so you might expect from a commercial perspective, it might take a visit or two longer than treatment of molluscum. That's sort of the goal. Some of the anecdotes we have for supporting, why do we think it's a large market? First, our clinical trial did enroll faster than our expectations.
It is placebo-controlled. Most patients, if there really are a lot of viable options for other therapies out there, would choose something else. We saw rapid enrollment and interest in our study because the opportunity to freeze or cut these lesions is painful, may lead to scarring, and are ineffective. YCANTH does represent a compelling option for them. Importantly, our Japanese partner, Shionogi, invested significant capital in this program, and they're providing the first $40 million of cost for this common wart trial, which is about 90% of the total cost, yet they retain only Japanese rights, and we will pay only back half of that capital at a future milestones.
It sort of supports in a market where the price is much lower, the population is smaller, there's still meaningful investment, and we don't believe they would have made that investment if they didn't believe in the opportunity of YCANTH to impact those patients.
What is the standard of care currently for common warts?
There is a variety of relatively ineffective take-home products, OTC products, where patients will struggle. It requires daily treatment, and the warts will either not go away or will recur. They can go to the doctor and get cryotherapy, which is painful and may lead to scarring, and is certainly not ideal for young children. One of the things we are trying to show with YCANTH in our common wart study is it goes on, it is relatively painless, and it is comfortable for the children and comfortable for the provider because they are not causing that trauma in the office.
Okay. As you think about the phase III readout that is going to be in the first quarter of next year, is there a specific bar that we should be thinking about that YCANTH needs to get over in order for it to be favorably reimbursed once you guys are commercial?
I think there are two aspects to that. One, YCANTH itself is covered today, so the pathway towards coverage should be more facile than it was for the first time with molluscum. In terms of the bar, given there is no approved product, that bar is beating placebo in a phase III clinical study. Obviously, our goal is to provide even better clearance rates than that. The efficacy bar the FDA set was complete clearance of all warts, whether you had one, two, three, four, five, six, et cetera. As we look at that number, both the clearance of all warts in a 12-week period, both the ones established at the beginning or new, is a critical endpoint. Also, how many visits does it take to clear three of those warts or two of those warts? Will it be meaningful to the clinicians and the patients?
Especially if one wart shows up at visit four that wasn't there, you're not expecting to clear that wart in one visit.
Okay.
Our expectation is a drug that's safe, that's efficacious, and hits its primary endpoint as the minimum bar, and then expecting that we might have additional data providing safety and efficacy well beyond that.
Shouldn't placebo sort of just be zero in this disease? I'm not that familiar with the pathophysiology of it, and if it comes and goes, I'm not sure.
They tend not to clear spontaneously on their own.
Yeah.
But it is a viral infection, so it can at some point. Because you are treating with placebo, which contains mostly acetone or ethanol, you wouldn't expect three treatments of acetone or ethanol, a small drop over that period of time to have an effect. But you will see some spontaneous resolution of warts. We accounted for that in our powering assumptions into the study, and the interim analysis hopefully confirmed those assumptions were appropriate.
What gives you confidence that you guys will show efficacy with YCANTH in this disease?
The confidence we have is based on our phase II results that we already conducted, where we saw over 50% of the patients cleared their warts, but also the historical experience with a variety of unregulated compounded formulations of cantharidin, where doctors, and especially dermatologists, felt comfortable that YCANTH was their go-to product of choice to try it.
Got it. Okay. Assuming both of these studies are positive, how soon can you file an sNDA with the FDA, and how soon can you get it approved?
The sNDA will have a normal review cycle. This is not a priority review, accelerated pathway. As soon as we have the top-line data from the second trial in mid-next year, we will engage with the FDA, confirm through a pre-NDA meeting what is required for the submission, if anything, beyond the normal activities, and then we will proceed as quickly as possible from there. Importantly, as we write the first CSR, we will have the study done about three months earlier. That will allow us some time to use that as a template for our next study.
Okay. Once you get this indication expansion, does that change your commercial infrastructure at all?
At this point, it should not materially impact our commercial infrastructure because many of them are the same call points. What we can certainly think about is, are there territories that we could expand into, or are some of our territories too large and we should add a second representative in larger metropolitan areas? It is something we will evaluate and continually evaluate. We feel very comfortable with the footprint we have established now, and we will incrementally adjust as the business needs demand.
Okay. I do not believe you guys have ever characterized what peak sales looks like for molluscum or common warts. Can you just help us dimensionalize it and just give us an idea?
Yeah. What I would say is, I'll just refer to some of the analyst reports that have been issued as a place, because we've not given specific guidance.
Okay.
There are estimates of molluscum being a $100 million-$200 million potential business. Common warts are 3.5x the addressable market, with likely more utilizations per patient. So we've frequently said it could be up to a multi-billion dollar business. So I think they're very, very large unmet needs. If you think about drugs and dermatological diseases out there, if you look molluscum, there's only two products available in a large indication. Common warts, there's zero.
If you look at psoriasis, atopic dermatitis, acne, there are several to dozens of products available for those.
It really gives us a great opportunity to make a differentiation on efficacy and safety for large populations.
Have you talked with doctors on the ground? You mentioned going after peds and derms.
Have you talked with them specifically about how often do they see common warts, and what would the value add be around YCANTH, and how excited they would be, and do they share in your enthusiasm?
What I will say is, one of the things we spend the most time in training our representative is to stay on label for YCANTH, because the question they will get asked the most by the clinician is, can I use this for warts? We emphasize that very strongly in all of our training and repeat efforts.
They will refer to our medical team if there are specific questions on that. Just that interest alone tells you there is demand. It is one of the most frequent questions we would get-
-in any type of ad board or medical conference.
Okay. Remind us your current cash balance and your runway.
We have about $14 million cash at the end of last quarter.
We just announced we have the ability to draw an additional $15 million from a credit facility that we unlocked this quarter, and we believe that cash runway gets us through the critical data readouts next year to the end of next year.
Okay. Lastly, in the last minute or two, just what do you think investors are just underappreciating about Verrica right now?
There's been a lot of challenges for this company historically. We've addressed many of them. We have a robust pipeline. It's not always transparent that we're running a global phase III program, but it's not utilizing our cash. We also have a pipeline program in oncology for basal cell carcinoma, with the potential to also treat Gorlin syndrome, which we're evaluating now.
We are very efficient. We also have some very long-standing and supportive investors. We're worried about every day executing on this business and positioning it for growth in the future. Sometimes people look at the revenue number and wish it was larger, growing faster, and what we're trying to do is run an efficient business cost-effectively that positions this company for rapid growth-
-over the long term. I think we're excited about the opportunity there, as well as the potential for expansion of the YCANTH franchise around the world. As you might be aware, a large percentage of children will get this disease. It doesn't matter where in the world you live. We've already engaged with EMA on engagement in Europe with no additional trials.
And we see continued interest around the world. I think those are lots of opportunities for investors. We focus on executing. I continue to say that is what we are going to do, tell you what we are going to do, and then do it. I think that is going to ultimately what resonates with investors going forward.
Perfect. I think that is all the time that we have today. It is great to see you.
Thank you very much.
Thanks for being here, and have a great conference.
Appreciate it.